NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: MARKSANS · data 2026-10-30
Marksans Pharma Limited
In plain words
Price: 12.8% below its 52-week high of ₹350.95.
Delivery: 45.2% of traded shares were kept for delivery over the last 10 sessions, against 39.0% over the last 60.
Latest results: a net profit of ₹157 cr for the quarter ended Jun 2026 (+169.5% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹3,172 cr |
| Net profit (last 12 months) | ₹517 cr |
| Sales growth, 3 years (yearly) | 16.7% |
| Profit growth, 3 years (yearly) | 16.2% |
At a glance
Promoters 43.9% (unchanged in a year), pledged 0.0%, institutions 24.6%.
P/E 26.9, dividend yield 0.3%. Price relative to earnings and book value (low is cheaper, not better).
ROE 15.2%, ROCE 16.3%, operating margin 19.3%: how much profit it earns on the money it uses.
Debt/equity 0.11, Profit growth 16.2% and sales growth 16.7% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Profit grew 16.2% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
MARKSANS Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹840.8 crore, up 35.6% YoY and down 1.8% QoQ.
Net profit was ₹157.17 crore, up 169.5% YoY and up 6.1% QoQ.
Operating margin was 25.3% (16.1% a year ago).
EPS was ₹3.47, up 169% YoY and up 6.1% QoQ.
MARKSANS के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹840.8 करोड़; पिछले साल की तुलना में 35.6% की बढ़त, पिछली तिमाही की तुलना में 1.8% की गिरावट।
शुद्ध मुनाफ़ा: ₹157.17 करोड़; पिछले साल की तुलना में 169.5% की बढ़त, पिछली तिमाही की तुलना में 6.1% की बढ़त।
ऑपरेटिंग मार्जिन: 25.3% (एक साल पहले 16.1%)।
EPS: ₹3.47; पिछले साल की तुलना में 169% की बढ़त, पिछली तिमाही की तुलना में 6.1% की बढ़त।
MARKSANSના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹840.8 કરોડ; ગયા વર્ષની સરખામણીએ 35.6% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 1.8% ઘટાડો.
ચોખ્ખો નફો: ₹157.17 કરોડ; ગયા વર્ષની સરખામણીએ 169.5% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 6.1% વધારો.
ઓપરેટિંગ માર્જિન: 25.3% (એક વર્ષ પહેલાં 16.1%).
EPS: ₹3.47; ગયા વર્ષની સરખામણીએ 169% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 6.1% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
15/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 10/30: Delivery 44.4% over the last 20 sessions vs 24.4% in the 40 before (1.82x); shares delivered per day 0.59x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend ● Results
- 20 Aug 26Dividend Dividend ₹0.9 (ex-date) -1.7% next session
- 12 Aug 26Results Q1 FY27 results: profit +169.5% YoY +8.8% next session
- 26 May 26Results Q4 FY26 results: profit +1533.2% YoY +13.2% next session
- 5 Feb 26Results Q3 FY26 results: profit +8.3% YoY +0.1% next session
- 13 Nov 25Results Q2 FY26 results: profit +1.6% YoY -2.3% next session
- 12 Aug 25Results Q1 FY26 results: profit −34.3% YoY -12.3% next session
- 1 Aug 25Dividend Dividend ₹0.8 (ex-date) -0.5% next session
- 19 May 25Results Q4 FY25 results: profit −88.6% YoY -1.9% next session
- 11 Feb 25Results Q3 FY25 results: profit +25.6% YoY -4.9% next session
- 12 Nov 24Results Q2 FY25 results: profit +15.8% YoY +5.9% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹841 cr | ₹157 cr | +169.5% | 25.3% | 3.47 |
| Mar 2026 | ₹856 cr | ₹148 cr | +1533.2% | 22.8% | 3.27 |
| Dec 2025 | ₹754 cr | ₹113 cr | +8.3% | 21.3% | 2.5 |
| Sept 2025 | ₹720 cr | ₹98 cr | +1.6% | 20.1% | 2.17 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 43.87% | 43.87% | 43.87% | 43.87% |
| Foreign institutions (FII) | 19.06% | 17.47% | 16.76% | 16.74% |
| Domestic institutions (DII) | 5.54% | 6.19% | 6.57% | 5.91% |
| Mutual funds | 3.72% | 4.36% | 4.66% | 4.41% |
| Retail investors | 23.42% | 24.33% | 24.59% | 25.34% |
| Number of shareholders | 2,47,508 | 2,46,635 | 2,46,279 | 2,55,153 |
Common questions
What was Marksans Pharma Limited's latest quarterly profit?
Marksans Pharma Limited reported a net profit of ₹157 cr for the quarter ended Jun 2026 (+169.5% on the same quarter a year earlier), on revenue of ₹841 cr.
How much do promoters hold in Marksans Pharma Limited?
Promoters held 43.87% of Marksans Pharma Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Marksans Pharma Limited debt-free?
Its latest reported debt-to-equity ratio is 0.11.
What is Marksans Pharma Limited's P/E ratio?
About 26.9, based on the last 12 months' earnings and a price of ₹306.2 (data 2026-10-30).
What is the 52-week high and low of Marksans Pharma Limited?
The 52-week high is ₹350.95 and the 52-week low is ₹155.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Marksans Pharma Limited | ₹306.2 | ₹14,279 cr | 26.9 | — | 15.2% | 16.3% | 0.11 | +66.7% |
| NATCO Pharma Limited | ₹782.4 | ₹15,350 cr | 12.4 | — | 16.9% | 15.6% | 0.08 | -4.8% |
| Jubilant Pharmova Limited | ₹923.8 | ₹14,729 cr | 41.7 | — | 6% | 6.5% | 0.51 | -19.6% |
| Indegene Limited | ₹586.8 | ₹14,161 cr | 34.5 | 4.2 | 13.9% | 15.9% | 0.05 | +7.5% |
| Corona Remedies Limited | ₹2,149.6 | ₹13,125 cr | 66.1 | — | 27.4% | 32.4% | 0.22 | +46.2% |
| Anupam Rasayan India Ltd. | ₹1,143.5 | ₹12,999 cr | 74.4 | — | 5.5% | 9% | 0.57 | +4.2% |
Compare MARKSANS with NATCOPHARM in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open MARKSANS in NSE Scanner →